Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed

Him & Hers Health (NYSE:HIMS) closed up ~10% Thursday after a federal court in Texas administratively closed a case in which a compounding drugs industry association challenged the U.S. FDA’s determination that Eli Lilly’s (NYSE:LLY) blockbuster